[1]
ALEXIS F., PRIDGEN E., MOLMAR L.K., FAROKHZAD O.C., Factors affecting the clearance and biodistribution of polymeric nanoparticles, Molecular Pharmaceutics 5, 4 (2008), pp.505-515.
DOI: 10.1021/mp800051m
Google Scholar
[2]
ALEXIS F., RHEE J-W., RICHIE J.P., RADOVIC-MORENO A. F., LANGER R., FAROKHZAD O.C., ew frontiers in nanotechnology for cancer treatment, Urologic Oncology: Seminars and Original Investigations 26 (2008), pp.74-85.
DOI: 10.1016/j.urolonc.2007.03.017
Google Scholar
[3]
AKIN D., STURGIS J., RAGHEB K., SHERMAN D., BURKHOLDER K., ROBINSON J.P., BHUNIA A.K., MOHAMMED S., BASHIR R., Bacteria-mediated delivery of nanoparticles and cargo into cells, Nature Nanotechnology 2 (2007), pp.441-449.
DOI: 10.1038/nnano.2007.149
Google Scholar
[4]
CAPRI S., CATTANEO G., Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy, Clinical Therapeutics 28, 6 (2003).
DOI: 10.1016/s0149-2918(03)80172-8
Google Scholar
[5]
CARUTHERS S.D., WICKLINE S.A., LANZA G.M., anotechnological applications in medicine, Current Opinion in Biotechnology 18 (2007), pp.26-30.
DOI: 10.1016/j.copbio.2007.01.006
Google Scholar
[6]
CHAN V.S.W., anomedicine: An unresolved regulatory issue, Regulatory Toxicology and Pharmacology 46 (2006), pp.218-224.
DOI: 10.1016/j.yrtph.2006.04.009
Google Scholar
[7]
CHERTOK B., MOFFAT B.A., DAVID A.E., YU F., BERGEMANN C., ROSS B.D., YANG V.C., Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors, Biomaterials 29, 4 (2007), pp.487-496.
DOI: 10.1016/j.biomaterials.2007.08.050
Google Scholar
[8]
CHO K., WANG X., NIE S., CHEN Z., SHIN D. M., Therapeutic nanoparticles for drug delivery in cancer, Clinical Cancer Res. 14, 5 (2008), pp.1310-1316.
DOI: 10.1158/1078-0432.ccr-07-1441
Google Scholar
[9]
DALLASTA L.M., PISAROV L.A., ESPLEN J.E., WERLEY J.V., MOSES A.V., NELSON J.A., ACHIM C.L., Blood-brain barrier tight junction disruption in human immuno deficiency virus-1 encephalitis, Am. J. pathol. 155, 6 (1999), p.1915-(1927).
DOI: 10.1016/s0002-9440(10)65511-3
Google Scholar
[10]
DECUZZI P., FERRARI M., The role of specific and non-specific interactions in receptormediated endocytosis of nanoparticles, Biomaterials 28 (2007), pp.2915-2922.
DOI: 10.1016/j.biomaterials.2007.02.013
Google Scholar
[11]
DUNCAN R., Polymer conjugates as anticancer nanomedicines, Nature Reviews 6 (2006), pp.688-701.
DOI: 10.1038/nrc1958
Google Scholar
[12]
FAN W., SUI M., HUANG Y., « Glucocorticoids selectively inhibit paclitaxel-induced apoptosis: Mechanisms and its clinical impact", Current Medicinal Chemistry 11 (2004), pp.403-411.
DOI: 10.2174/0929867043455990
Google Scholar
[13]
FAROKHZAD M.C., LANGER R., anomedicine: Developing smarter therapeutic and diagnostic modalities", Advanced Drug Delivery Reviews 58 (2006).
DOI: 10.1016/j.addr.2006.09.011
Google Scholar
[15]
FERRARI M., anovector therapeutics, Current Opinion in Chemical Biology 9 (2004), pp.343-346.
Google Scholar
[16]
FERRARI M., The mathematical engines of nanomedicine, Small Journal 4 (2008) p. (2025).
Google Scholar
[17]
GAO K., JIANG X., Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles, Pharmaceutical nanotechnology (2006).
DOI: 10.1016/j.ijpharm.2005.11.040
Google Scholar
[18]
GU F.X., KARNIK R., WANG A.Z., ALEXIS F., LEVY-NISSENBAUM E., HONG S., LANGER R.S., FAROKHZAD O.C., Targeted nanoparticles for cancer therapy, Nanotoday 2, 3 (2007), pp.14-21.
DOI: 10.1016/s1748-0132(07)70083-x
Google Scholar
[19]
HEATH J. R., DAVIS M. E., anotechnology and cancer, Annual Review of Medicine 59 (2008), pp.251-265.
Google Scholar
[20]
HELDIN C. -H., RUBIN K., PIETRAS K., OSTMAN A., High interstitial fluid pressure - An obstacle in cancer therapy, Nature Reviews 4 (2004), pp.806-813.
DOI: 10.1038/nrc1456
Google Scholar
[21]
HOLLIGER P., HUDSON P.J., Engineered antibody fragments and the rise of single domains, Nature Biotechnology 23 (2005), pp.1126-1136.
DOI: 10.1038/nbt1142
Google Scholar
[22]
HOLMBERG S.B., FORSSELL-ARONSSON E., GRETARSDOTTIR J., JACOBSSON L, RIPPE B., Vascular clearance by the reticulo-endothelial system - Measurements using two different-sized albumincolloids, Scandinavian Journal of Clinical and Laboratory Investigation 50, 8 (1990).
DOI: 10.3109/00365519009104954
Google Scholar
[23]
IMAI K., TAKAOKA A., Comparing antibody and small-molecule therapies for cancer, Nature Reviews Cancer 6 (2006), pp.714-727.
DOI: 10.1038/nrc1913
Google Scholar
[24]
JAIN K. K., Applications of nanobiotechnology in clinical diagnostics, Clinical Chemistry 53, 11 (2007), p.2002-(2009).
Google Scholar
[25]
JALLOULI Y., PAILLARD A., CHANG J., SEVIN E., BETBEDER D., Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro, International Journal of Pharmaceutics 344 (2007), pp.103-109.
DOI: 10.1016/j.ijpharm.2007.06.023
Google Scholar
[26]
JUILLERAT-JEANNERET L., The targeted delivery of cancer drugs across the bloodbrain barrier : Chemical modifications of drugs or drug-nanoparticles?, Drug Discovery Today 13, 23 (2008), pp.1099-1106.
DOI: 10.1016/j.drudis.2008.09.005
Google Scholar
[27]
KLOOVER J.S., DEN BAKKER M.A., GELDERBLOM H., VAN MEERBEECK J., Fatal outcome of a hypersensitivity reaction to paclitaxel: A critical review of premedication regimens, British Journal of cancer 90 (2004).
DOI: 10.1038/sj.bjc.6601303
Google Scholar
[29]
LEE KOO Y. -E., REDDY G.R., BHOJANI M., SCHNEIDER R., PHILBERT M.A., REHEMTULLA A., ROSS B.D., KOPELMAN R., Brain cancer diagnosis and therapy with nanoplatforms, Advanced Drug Delivery Reviews 58, 14 (2006), pp.1556-1577.
DOI: 10.1016/j.addr.2006.09.012
Google Scholar
[30]
LIU Y., MIYOSHI H., NAKAMURA M., « anomedicine for drug delivery and imaging : A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles », International Journal of Cancer 120 (2007), pp.2527-2537.
DOI: 10.1002/ijc.22709
Google Scholar
[31]
LUNT S.J., KALLIOMAKI T.M.K., BROWN A., YANG V.X., MILOSEVIC M., HILL R.P., Interstitial Fluid Pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumors, BMC Cancer 8, 2 (2008), 14p.
DOI: 10.1186/1471-2407-8-2
Google Scholar
[32]
MING-CHENG CHENG M., CUDA G., BUNIMOVICH Y.L., GASPARI M., HEATH J.R., HILL H.D., MIRKIN C.A., NIJDAM A.J., TERRACCIANO R., THUNDAT T., FERRARI M., anotechnologies for biomolecular detection and medical diagnostics, Current Opinion in Chemical Biology 10 (2006).
DOI: 10.1016/j.cbpa.2006.01.006
Google Scholar
[33]
MISRA A., GANESH S., SHAHIWALA A., Drug delivery to the central nervous system: A review, J. Pharm. Pharmaceut. Sci 6, 2 (2003), pp.252-273.
Google Scholar
[34]
OJEDA B., DE SANDE L.M., CASADO A., MERINO P., CASADO M.A., Costeffectiveness analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain, British Journal of Cancer 89, 6 (2003).
DOI: 10.1038/sj.bjc.6601228
Google Scholar
[35]
OWENS D.E., PEPPAS N.A., Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, International Journal of Pharmaceutics 307, 1 (2006), pp.93-102.
DOI: 10.1016/j.ijpharm.2005.10.010
Google Scholar
[36]
OZBEN T., Mechanisms and strategies to overcome multiple drug resistance in cancer, FEBS Letters 580 (2006), pp.2903-2909.
DOI: 10.1016/j.febslet.2006.02.020
Google Scholar
[37]
PANCHAPAKESAN B., anotechnology: Tiny technology - tremendous therapeutic potential, Oncology Issues November/December (2005).
Google Scholar
[38]
PARK J.W., Lipsome-based drug delivery for breast cancer treatment, Breast Cancer Research 4 (2002), pp.95-99.
Google Scholar
[39]
PRASAD P.N., ROY I., BERGEY E.J., OHULCHANSKY T.Y., PUDAVAR H., Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles, Trends in Nanomaterials.
Google Scholar
[40]
PRATO M., KOSTARELOS K., BIANCO A., Functionalized carbon nanotubes in drug design and discovery", Accounts of Chemical Research 441 (2008).
DOI: 10.1021/ar700089b
Google Scholar
[42]
ROY I., OHULCHANSKYY T.Y., PUDAVAR H.E., BERGEY E.J., OSEROFF A.R., MORGAN J., DOUGHERTY T.J., PRASAD P.N., Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: A novel drug-carrier system for photodynamic therapy, Journal of the American Chemical Society 125, 26 (2003).
DOI: 10.1021/ja0343095
Google Scholar
[43]
SANVICENS N., MARCO M.P., Multifunctional nanoparticles - Properties and prospects for their use in human medicine, Trends in Biotechnology 26, 8 (2008), p.425433.
DOI: 10.1016/j.tibtech.2008.04.005
Google Scholar
[44]
SENGUPTA S., SASISEKHARAN R., Exploiting nanotechnology to target cancer, British Journal of Cancer 96 (2007), pp.1315-1319.
DOI: 10.1038/sj.bjc.6603707
Google Scholar
[45]
SINHA R., KIM G. J., NIE S., SHIN D. M., anotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery, Molecular Cancer Therapeutics 5, 8 (2006), p.1909-(1917).
DOI: 10.1158/1535-7163.mct-06-0141
Google Scholar
[46]
SMITH D.H., ADAMS J.R., JOHNSTON S.R.D., GORDON A., DRUMMOND M.F., BENNETT C.L., A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the U.S.A. and the U.K., Annals of Oncology 13 (2002).
DOI: 10.1093/annonc/mdf275
Google Scholar
[47]
SOUZA G.R., CHRISTIANSON D.R., STAQUICINI F.I., OZAWA M.G., SNYDER E.Y., SIDMAN R.L., MILLER J.H., ARAP W., PASQUALINI R., etworks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents, PNAS 103, 5 (2006).
DOI: 10.1073/pnas.0509739103
Google Scholar
[48]
STEINFELD U., PAULI C., KALTZ N., BERGEMANN C., LEE H. -L., T lymphocytes as potential therapeutic drug carrier for cancer treatment, International Journal of Pharmaceutics 311 (2006), pp.229-236.
DOI: 10.1016/j.ijpharm.2005.12.040
Google Scholar
[49]
SURI S.S., FENNIRI H., SINGH B., « anotechnology-based drug delivery systems », Journal of Occupational Medicine and Toxicology (2), 2007, 6p.
Google Scholar
[50]
TAN K., CHEANG P., HO I.A., LAM P.Y., HUI K.M., anosized bioceramic particles could function as efficient gene delivery vehicles with target specificity for the spleen, Gene Therapy 14, 10 (2007), pp.828-835.
DOI: 10.1038/sj.gt.3302937
Google Scholar
[51]
TANAKA T., DECUZZI P., CRISTOFANILLI M., SAKAMOTO J.H., TASCIOTTI E., ROBERTSON F.M., FERRARI M., anotechnology for breast cancer therapy", Biomed Microdevices (2008).
DOI: 10.1007/s10544-008-9209-0
Google Scholar
[53]
TOMALIA D.A., REYNA L.A., SVENSON S., « Dendrimers as multi-purpse nanodevices for oncology drug delivery and diagnostic imaging », Biochemical Society Transactions 35 (2007), pp.61-67.
DOI: 10.1042/bst0350061
Google Scholar
[54]
TORCHILIN VP, Multifunctional nanocarriers, Advanced Drug Delivery Reviews 58 (2006), pp.1532-1555.
DOI: 10.1016/j.addr.2006.09.009
Google Scholar
[55]
TORCHILIN V., Multifunctional and stimuli-sensitive pharmaceutical carriers, European Journal of Pharmaceutics and Biopharmaceutics (2008).
Google Scholar
[56]
XiANG L., BIN W., HUALI J., WEI J., JIESHENG T., FENG G., YING L., Bacterial magnetic particles (BMPs)-PEI as a novel and efficiënt nonviral gene delivery system, The Journal of Gene Medicine 9 (2007), pp.679-690.
DOI: 10.1002/jgm.1068
Google Scholar
[57]
WANG X., YANG L., CHEN Z., SHIN D.M., Application of nanotechnology in cancer therapy and imaging, CA Cancer J Clin 58, 2 (2008), pp.97-110.
Google Scholar
[58]
WU H. -C., CHANG D. -K., HUANG C. -T., Targeted therapy for cancer, Journal of Cancer Molecules 2, 2 (2006), pp.57-66.
Google Scholar
[59]
YEZHELYEV M.V., GAO X., XING Y., AL-HAJJ A., NIE S., O'REGAN R.M., Emerging use of nanoparticles in diagnosis and treatment of breast cancer, Lancet Oncology 7 (2006), pp.657-667.
DOI: 10.1016/s1470-2045(06)70793-8
Google Scholar
[60]
YIH T.C., AL-FANDI M., Engineered nanoparticles as precise drug delivery systems, Journal of Cellular Biochemistry 97 (2006), pp.1184-1190.
DOI: 10.1002/jcb.20796
Google Scholar
[61]
ZHANG L., GU F.X., CHAN J.M., WANG A.Z., LANGER R.S., FAROKZHAD O.C., anoparticles in medicine: Therapeutic applications and developments, Clinical Pharmacology & Therapeutics 83, 5, pp.761-76.
Google Scholar